Tioga Pharmaceuticals, Inc.

Product Development

Tioga Pharmaceuticals is engaged in the development of novel therapies for the treatment of gastrointestinal diseases. Tioga's lead compound, asimadoline, is currently in clinical development for the treatment of irritable bowel syndrome (IBS).

Tioga's clinical development programs are led by its Chief Medical Officer, Allen Mangel M.D. Ph.D.
Dr. Mangel was formerly Worldwide Head of Gastroenterology Clinical Development for GlaxoSmithKline.

About Asimadoline
Asimadoline is a proprietary, peripherally restricted small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. In 2005, Tioga acquired all worldwide rights to asimadoline from Merck. Asimadoline was originally developed to treat peripheral pain such as arthritis. It has been tested in over 1,000 subjects and has demonstrated a promising safety profile.

Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. Kappa opioid receptors are found mostly in the digestive tract and are believed to play an important role in control of visceral pain and bowel motility. As such, kappa opioid agonists are ideal candidates to relieve the pain, discomfort an impaired motility common to IBS and other gastrointestinal disorders.

Asimadoline has demonstrated statistically significant results in treating Irritable Bowel Syndrome patients in a recently completed 596 subject phase 2b randomized, double blind, placebo-controlled, dose ranging, clinical trial. ...read the latest press-release

Tioga initiated a phase 3 clinical trial of asimadoline for the treatment of D-IBS in Q2 2010.

IBS Asimadoline has demonstrated statistically significant results in treating Irritable Bowel Syndrome (IBS) patients in a recently completed 596 subject phase 2b randomized, double blind, placebo-controlled, dose ranging, clinical trial.

Asimadoline produced significant improvement in diarrhea-predominant patients across multiple parameters including: pain, urgency, frequency and bloating in both males and females. Effects occurred during the first month of treatment and persisted throughout the three months of treatment. Benefit was also seen in alternating IBS patients. Asimadoline appeared to be well tolerated with no Adverse Event occurring in a dose-dependent manner. ...read the latest press-release